This clinical trial is focused on studying a type of cancer called esophageal squamous cell carcinoma, which affects the esophagus, the tube that carries food from the mouth to the stomach. The study is specifically for elderly patients who are not able to undergo traditional chemotherapy treatments. The treatment being tested is a medication called Tislelizumab, also known by its code names BGB-A317 and JHL-2108. Tislelizumab is given as an infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of this study is to evaluate the safety and effectiveness of Tislelizumab in treating elderly patients with advanced esophageal squamous cell carcinoma who cannot receive standard chemotherapy. Participants in the study will receive Tislelizumab and will be monitored over a period of time to see how well they respond to the treatment. The study aims to assess how many patients are still alive six months after starting the treatment and to gather information on their overall health and quality of life during this period.

Throughout the study, researchers will also look at various factors such as the safety of the treatment, the overall survival of patients, and how the cancer responds to the medication. The study will also consider the expression of a protein called PD-L1, which may influence how well the treatment works. Additionally, the study will evaluate the quality of life of the patients and other health-related factors to provide a comprehensive understanding of the treatment’s impact.